A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial.
(2013) In Annals of Oncology 24(9). p.2335-2341- Abstract
- The main objective was to study the effect on progression-free survival (PFS) of adding erlotinib to bevacizumab as maintenance treatment following chemotherapy and bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC).
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3913091
- author
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Annals of Oncology
- volume
- 24
- issue
- 9
- pages
- 2335 - 2341
- publisher
- Oxford University Press
- external identifiers
-
- wos:000323963100020
- pmid:23788755
- scopus:84883339111
- ISSN
- 1569-8041
- DOI
- 10.1093/annonc/mdt236
- language
- English
- LU publication?
- no
- id
- cbc307cd-b479-4a04-bb4d-7eb9196c2887 (old id 3913091)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/23788755?dopt=Abstract
- date added to LUP
- 2016-04-01 10:21:00
- date last changed
- 2022-02-10 01:15:36
@article{cbc307cd-b479-4a04-bb4d-7eb9196c2887, abstract = {{The main objective was to study the effect on progression-free survival (PFS) of adding erlotinib to bevacizumab as maintenance treatment following chemotherapy and bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC).}}, author = {{Johnsson, Anders and Hagman, Helga and Frödin, Jan-Erik and Berglund, Åke and Keldsen, N. and Fernebro, Eva and Sundberg, J and De Pont Christensen, R and Garm Spindler, K-L and Bergström, D and Jakobsen, A}}, issn = {{1569-8041}}, language = {{eng}}, number = {{9}}, pages = {{2335--2341}}, publisher = {{Oxford University Press}}, series = {{Annals of Oncology}}, title = {{A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial.}}, url = {{http://dx.doi.org/10.1093/annonc/mdt236}}, doi = {{10.1093/annonc/mdt236}}, volume = {{24}}, year = {{2013}}, }